Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05979779 · ClinicalTrials.gov registry record · Phase 2
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
A Phase 2 study of Non-alcoholic Fatty Liver Disease and Fatty Liver, sponsored by Rivus Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 219
- Enrollment target
- 20
- Study locations
NCT05979779 is a Phase 2 study of Non-alcoholic Fatty Liver Disease and Fatty Liver that is active but no longer recruiting, run by Rivus Pharmaceuticals. The registered enrollment target is 219 participants, above the 186-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05979779, a Phase 2 study of Non-alcoholic Fatty Liver Disease and Fatty Liver, is active but no longer recruiting, sponsored by Rivus Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 219 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) during this time. The end-of-study visit will take place approximately 4 weeks after the last dose of the study drug (Week 30).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG HU6
Study Locations (20)
Florida
- Synergy Healthcare - Bradenton
- ABMED Clinical Research Corp. - Cape Coral
- Southwest General Healthcare Center - Fort Myers
- Miami Clinical Research - Miami
- Advanced Clinical Research - Miami
- Century Research, LLC - Miami
- Entrust Clinical Research - Miami
- Panax Clinical Research - Miami Lakes
California
- ProSciento CRU - Chula Vista
- Velocity Clinical Research - Los Angeles
- Catalina Research Institute - Montclair
- Northern California Research Center - Sacramento
- Metro Clinical Trials - San Bernardino
Texas
- IMA Clinical Research-Austin - Austin
- Mt Olympus Medical Research - Houston
- Houston Research Institute - Houston
- Texas Liver Institute - San Antonio
Louisiana
- Tandem Clinical Research - Marrero
New Jersey
- CenExel HRI - Berlin
North Dakota
- Lillestol Research - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2023-09-05 |
| Est. Completion | 2025-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05979779
The ClinicalTrials.gov registry entry for NCT05979779 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (18% higher). The listed sponsor is Rivus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05979779 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT05979779 about?
NCT05979779 is a clinical study titled "Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis". This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetic...
What is the current status of trial NCT05979779?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 219 participants. The study started on 2023-09-05. Estimated completion is 2025-06.
What conditions does trial NCT05979779 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT05979779?
The interventions under investigation include: Placebo (OTHER), HU6 (DRUG).
Who is sponsoring clinical trial NCT05979779?
This trial is sponsored by Rivus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05979779 being conducted?
This trial has 20 study locations across California, Florida, Louisiana, New Jersey, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
RECRUITING · Phase 2
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2b Study of GSK4532990 in Adults With NASH
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.